BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
| Revenue (TTM) | $5.74B |
| Gross Profit (TTM) | $5.07B |
| EBITDA | $825.39M |
| Operating Margin | 16.50% |
| Return on Equity | 12.40% |
| Return on Assets | 5.96% |
| Revenue/Share (TTM) | $52.14 |
| Book Value | $42.84 |
| Price-to-Book | 6.77 |
| Price-to-Sales (TTM) | 5.61 |
| EV/Revenue | 5.15 |
| EV/EBITDA | 33.24 |
| Quarterly Earnings Growth (YoY) | 16971.00% |
| Quarterly Revenue Growth (YoY) | 35.50% |
| Shares Outstanding | $94.90M |
| Float | $1.01B |
| % Insiders | 17.30% |
| % Institutions | 32.99% |
Volatility is currently expanding